Propafenone (HCl)

Propafenone (HCl) is antiarrhythmic agent. Its spectrum of action is very similar to that of quinidine. Its potency as a sodium channel blocker is similar to that of flecainide. It has some structural similarities to propranolol and possess weak ß-adrenergic blocking activity.

Propafenone (HCl) is primarily indicated in conditions like Cardiac arrhythmia, Supraventricular tachycardia, Ventricular arrhythmias, Paroxysmal supraventricular tachyarrhythmias.

Propafenone (HCl) is contraindicated in conditions like Cardiogenic shock, Congestive heart failure, Hypotension, Bradycardia, Myasthenia gravis, Obstructive airway disease.

Propafenone (HCl) produces potentially life-threatening effects which include Bradycardia, Hypotension. which are responsible for the discontinuation of Propafenone (HCl) therapy. The symptomatic adverse reactions produced by Propafenone (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Diarrhea, Constipation, Visual disorders, Dry mouth, Blurred vision, Vertigo, Taste disturbance, Weakness, Dyspnea, Wild complex tachycardia, Palpitations, Tremor, Anorexia, Diarrhea, Ataxia, Angina, CHF, Sinus arrest.

Propafenone should be used only when clearly needed during pregnancy.

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

2.14 to 4.29 mg/kg (3.2 (3.215)) 8 hourly PO — -

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Propafenone (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmiodarone (HCl)Increased myocardial depression and increased risk of ventricular arrhythmias when amiodarone given with other antiarrhythmics (e.g Propafenon). ADVICE: Avoid concomitant use or only undertaken with caution and appropriate monitoring.AmprenavirAmprenavir possibly increases plasma concentration of Propafenone; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorCimetidine (HCl)Desipramine (HCl)DextromethorphanDigoxinPropafenone may increase the serum concentration of Digoxin.ModerateMonitor increased serum concentrations/toxic effects of Digoxin if propafenone is initiated/dose increased, or decreased serum concentrations/effects if propafenone is discontinued/dose decreased.Distigmine (Br)LignocaineMetoprolol (Tartrate)Combined use of both drugs increases Plasma conc of former agentNelfinavirParoxetinePyridostigmine (Br)QuinidineRifampicinRitonavirRivastigmineTheophyllineVORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongationWarfarin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store Below 40°C. Protect from Sunlight and Moisture.